Skip to main content
Clinical Trials/NCT04531241
NCT04531241
Completed
Not Applicable

Clinical Evaluation of Senofilcon A Contact Lenses Using a Novel Manufacturing Technology

Johnson & Johnson Vision Care, Inc.7 sites in 1 country136 target enrollmentAugust 5, 2020
ConditionsVisual Acuity

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Visual Acuity
Sponsor
Johnson & Johnson Vision Care, Inc.
Enrollment
136
Locations
7
Primary Endpoint
Overall CLUE Comfort
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

This study is a multi-site, randomized, double-masked, 2×2 crossover design, 1-week dispensing study. Subjects will wear bilaterally both Test and Control lenses in a random order for 1-week each as a daily disposable modality with a wash-out period of 1 week between the wearing periods.

Registry
clinicaltrials.gov
Start Date
August 5, 2020
End Date
September 25, 2020
Last Updated
4 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
  • Appear able and willing to adhere to the instructions set forth in this clinical protocol.
  • Must be at least 18 and not more than 70 years of age (including 70) at the time of screening.
  • The subject must be a habitual and adapted wearer of daily disposable contact lenses in both eyes (at least 1 month of daily wear).
  • The subject must have normal eyes (i.e., no ocular medications or infections of any type).
  • The subject's required spherical contact lens prescription must be in the range of -0.50 to -3.25 and -3.75 to -6.00 D in each eye.
  • The subject's refractive cylinder must be ≤0.75D in each eye, if present
  • The subject must have best corrected visual acuity of 20/25 or better in each eye.

Exclusion Criteria

  • Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
  • Any systemic disease, autoimmune disease, or use of medication that may interfere with contact lens wear. (at the discretion of the investigator)
  • Any previous, or planned, ocular or interocular surgery (e.g., radial keratotomy, PRK, LASIK, etc.).
  • Any ocular infection.
  • Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
  • Monovision or multi-focal contact lens correction.
  • Participation in any contact lens or lens care product clinical trial within 7 days prior to study enrollment.
  • History of binocular vision abnormality or strabismus.
  • Any infectious disease (e.g., hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g., HIV, by self-report).
  • Suspicion of or recent history of alcohol or substance abuse.

Outcomes

Primary Outcomes

Overall CLUE Comfort

Time Frame: 1-Week Follow-up

Overall comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.

Overall CLUE Vision

Time Frame: 1-Week Follow-up

Overall vision was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.

Secondary Outcomes

  • Visual Performance(1-Week Follow-up)
  • Average Daily Wear Time (in Hours)(1-Week Follow-up)

Study Sites (7)

Loading locations...

Similar Trials